Gelonghui, April 15 | Junshengtai Pharmaceutical-B (2511.HK) bucked the trend in the afternoon. At one point, it surged more than 44% to HK$6.2, recovering lost ground since April. The stock price hit a new high of about three weeks since March 26, with a market value of about HK$3.2 billion. In early April, Junshengtai Pharmaceutical announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberibe) independently developed by the company has completed patient enrollment. The trial targets patients with type 2 diabetes (T2DM) or metabolic fatty hepatosis with prediabetes. According to reports, Junshengtai was founded in 2011 to focus on the discovery, development and commercialization of multi-functional, multi-target pioneering therapies to treat metabolic and digestive diseases. The company has successfully obtained material patents for HTD1801 in many countries and regions such as the United States, China, the European Union and Japan, and has obtained crystal patents in the US and China, forming an important competitive barrier.